Parsortix Update

RNS Number : 4867T

Angle PLC

07 December 2011

 



For immediate release

7 December 2011

ANGLE plc ("the Company")

Parsortix Update

UNIVERSITY OF SURREY RESEARCH PARTNERSHIP   

ANGLE plc (AIM : AGL) is pleased to announce that Parsortix Inc ("Parsortix"), its 90% owned portfolio company which specialises in medical diagnostics has signed a research agreement with the University of Surrey's Oncology Department ("the Department"). 

The Department works alongside the Royal Surrey Hospital and is a leading UK cancer research centre.  It is lead by Professor Hardev Pandha, who has had acclaim for his cancer research work, particularly in prostate cancer where the group has developed a urine diagnostic test which is considered to be more effective than the current PSA test. 

Professor Pandha will be leading the Department's work to evaluate the Parsortix cancer cell separation device.  The work will include a structured investigation of the Parsortix device's capability in capturing circulating tumour cells (CTCs) from cancer patient blood and optimisation of this process compared to the "spiked blood" previously used.

The first phase of work will focus on the optimisation, enumeration and characterisation of the captured CTCs.  The aim is to report initial results in Q1 2012.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"ANGLE intends to establish research partnerships with several leading cancer research centres.  We are delighted to be establishing the first such partnership with the University of Surrey's oncology department."

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Stephen Keys, Adrian Hargrave (Nominated adviser) Andy Roberts (Sales)	020 7397 8900
Buchanan Lisa Baderoon	020 7466 5000
Scott Harris Stephen Scott, James O'Shaughnessy, Harry Dee	0207 653 0030

About the University of Surrey's Oncology Department

http://www2.surrey.ac.uk/pgms/research/cancer/index.htm  

The oncology group at the Postgraduate Medical School, University of Surrey are a multidisciplinary team of cancer physicians and scientists who have an aim to develop, evaluate and deliver novel cancer therapies to patients. They have specialist expertise in urological and ovarian cancers, and conduct early phase trials across most cancer types.

The team is led by Prof Hardev Pandha, a clinician scientist and consultant in medical oncology, and Dr Richard Morgan, Senior lecturer in molecular oncology.  In particular the group have the expertise and facilities to undertake human studies of cancer vaccines and oncolytic viral therapy for cancer. Clinical trials are conducted at St Luke's Cancer Centre, in the neighbouring Royal Surrey County Hospital.

A particular strength of the group has been the emphasis on translational science associated with the trials. This includes the collection, archiving and evaluation of patient tissue and blood for biomarkers and discovery. The group currently numbers 24, has state-of-the-art laboratory facilities and scientific expertise to undertake new research projects with potential collaborators. The group has published 110 peer reviewed scientific papers since they moved to Surrey in 2006.

 

END

 

 

MSCKQLFBFLFEFBX